SPH Health Commerce

Name

SPH Health Commerce

Legal name

上药云健康 (Shanghai Pharma Cloud Health)

Website

https://sphcchina.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

501–1,000 employees

Short description

SPH Health Commerce (上药云健康) is a Chinese healthtech subsidiary of Shanghai Pharmaceuticals operating China's largest DTP pharmacy network (200+ specialty pharmacies across 25 provinces) to deliver full-lifecycle innovative drug commercialization services to 300+ pharmaceutical partners, hospitals, and 6M+ patients.

Ownership category

akta.pro rank

Product category

Specialty Pharmacy & Pharmaceutical Commercialization Services

NAICS

Pharmacies and Drug Retailers (45611)

SIC

Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC)

Keywords

• Specialty pharmacy services
• DTP drug distribution
• Pharmaceutical commercialization
• Internet hospital platform
• Innovative drug access

Headquarters

HQ city

Xuhui

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharma Company Commercialization Services: Fees from pharmaceutical companies for first-order landing support, precise marketing, drug registration, clinical trial supply, patient recruitment, and post-market data collection. Revenue tied to successful product launches and market penetration.
2. DTP/ Specialty Pharmacy Dispensing: Revenue from dispensing innovative (新特药) drugs through the 200+ '益药·药房' specialty pharmacy network, including both self-pay and insurance-reimbursed prescriptions. Supports rare disease, outpatient infusion, and chronic disease medications.
3. Innovative Payment Solutions: Revenue from insurance direct pay arrangements, patient assistance programs (with foundations), and managed care/TPA partnerships that facilitate reimbursement for high-cost medications.
4. Internet Hospital & Teleconsultation: Revenue from chronic disease teleconsultation, prescription circulation services, and internet hospital collaborations through the cloud pharmacy platform.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

SPH Health Commerce operates China's largest DTP (Direct-to-Patient) specialty pharmacy network (200+ 'Yiyao Pharmacy' stores covering 25 provinces and 66 cities) paired with a cloud pharmacy / internet hospital platform that delivers full-lifecycle commercialization services for innovative drugs. Its offerings span B2B services for pharmaceutical companies (first-order landing, clinical trial supply, precise marketing, real-world data collection) and B2C services for patients (specialty drug dispensing, chronic disease teleconsultation, innovative insurance/patient assistance programs). The platform handles 80%+ of innovative drug first-order landings in China and serves 6M+ cumulative patients.

Differentiator

Problem solved

Functional benefit

Brands

• 益药·药房 (Yiyao Pharmacy): Professional pharmacy network operated by Shanghai Pharma Cloud Health, providing innovative drug commercialization and patient services across 200+ locations in 25 provinces and 66 cities.

Products and services

• Yiyao Pharmacy (益药·药房) DTP Pharmacy Network China's largest DTP (Direct-to-Patient) specialty pharmacy network, providing retail dispensing of innovative drugs (新特药), rare disease medications, outpatient infusion services, and chronic disease medications. Operates 200+ professional pharmacies across 25 provinces and 66 cities, staffed by 400+ professional pharmacists. Serves 6M+ cumulative patients across 6+ major disease groups and 130+ major disease categories. Handles both self-pay and insurance-reimbursed prescriptions, including insurance direct pay (TPA) integration.
• Cloud Pharmacy (云药房)

Quantifiable outcome

• Over 80% of innovative drug first-order landings in China are achieved through SPH Health Commerce's platform.
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• ChiesicoreStrategic or Co-development Partner · 12 March 2026Italian multinational pharmaceutical company Chiesi has signed agreements with JD Health and SPH Health Commerce as part of its deepened strategic presence in China. Chiesi has launched more products in China over the past two years than in any other country globally, and views China as a co-development ground rather than merely an export market. The partnership with SPH Health Commerce likely supports commercialization and market access for Chiesi's innovative products in China.
• JD HealthcoreStrategic or Co-development Partner · 12 March 2026JD Health (JD.com's healthcare subsidiary) has entered into agreements with SPH Health Commerce alongside Chiesi as part of multi-party strategic collaboration. This partnership enables integration between SPH Health Commerce's DTP pharmacy network and JD Health's e-commerce and logistics infrastructure for pharmaceutical product distribution in China.
• ZambonminorStrategic or Co-development Partner · 12 March 2026Italian pharmaceutical company Zambon obtained regulatory approval and launched Fluimucil IV in China following a clinical development program conducted entirely in the country. While not explicitly confirmed as a direct SPH Health Commerce partner, Zambon's China market strategy of local clinical trials and product launches aligns with SPH Health Commerce's core service offering of supporting pharmaceutical company commercialization in China.
• BraccominorStrategic or Co-development Partner · 12 March 2026Italian pharmaceutical company Bracco is expanding its Chinese manufacturing facility through a 20 million euro investment phase with partner Shanghai Pharma. As SPH Health Commerce is a subsidiary of Shanghai Pharma, this investment in Shanghai Pharma's manufacturing partner may indirectly benefit SPH Health Commerce's product portfolio and supply chain capabilities.
• RecordatiminorStrategic or Co-development Partner · 12 March 2026Italian pharmaceutical company Recordati received approval for Signifor LAR in China in 2025, demonstrating its commitment to the Chinese market as a co-development ground. While not explicitly confirmed as a direct SPH Health Commerce partner, Recordati's regulatory milestone and China market entry strategy aligns with SPH Health Commerce's service model.

Scale indicators8 records

Direct peers

• JD Health: JD.com's healthcare subsidiary operates online pharmacy, teleconsultation, and pharmaceutical distribution in China. Direct competitor in online pharmacy and pharmaceutical e-commerce, and notably a partner of SPH Health Commerce in the Chiesi collaboration.
• Alibaba Health: Alibaba Group's healthcare arm operates one of China's largest online pharmacy platforms alongside pharmaceutical traceability, teleconsultation, and consumer healthcare services. Directly competes with SPH Health Commerce in online pharmacy and prescription routing.
• Ping An Healthcare and Technology: Operates one of China's largest internet healthcare platforms, combining teleconsultation, online pharmacy, and consumer health services. Overlapping with SPH Health Commerce on cloud pharmacy, teleconsultation, and innovative payment solutions.
• Yifeng Pharmacy Chain (益丰药房): One of China's largest retail pharmacy chains with thousands of physical outlets. Comparable specialty drug and chronic disease retail presence, though with less focus on innovative drug commercialization and B2B pharma services.
• 111 Inc. Chinese B2B/B2C online pharmacy platform combining drug distribution with digital health services. Comparable in offering a hybrid online-physical pharmacy model serving both pharma companies and patients in China.
• Yixintang Pharmacy (一心堂): Major Chinese retail pharmacy chain operating thousands of stores across southern and southwestern China. Comparable in physical pharmacy scale and chronic disease medication focus, though less differentiated in specialty/innovative drugs.

Broad incumbents

• China Resources Pharmaceutical Commercial Group: Subsidiary of China Resources group operating one of China's largest pharmaceutical distribution and retail networks. Comparable in pharmaceutical distribution scale and DTP-style specialty drug delivery infrastructure.
• Shanghai Pharmaceuticals Holding: SPH Health Commerce's parent company and one of China's largest pharmaceutical conglomerates spanning manufacturing, distribution, and retail. Comparable in the pharmaceutical distribution and retail pharmacy segments, with far broader scale and product portfolio.
• McKesson Corporation: Global pharmaceutical distribution and specialty pharmacy leader. Comparable in specialty pharmacy operations, pharma commercialization services, and patient support programs — though operating at vastly larger scale across global markets.
• CVS Health (CVS Specialty): US healthcare conglomerate with extensive specialty pharmacy operations through CVS Specialty. Comparable in specialty drug dispensing, patient assistance programs, and insurance integration — albeit with a much broader retail health footprint.

Market position

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SPH Health Commerce